Race for coronavirus treatment - As the global race continues to try and find a treatment for coronavirus the UK biotech firm Synairgen is reportedly planning to trial its experimental lung drug on Covid-19 patients.
The company received the green light from UK regulators to conduct a trial of its lead drug SNG001 at NHS trusts across the country.
The inhaled drug has been in development as a treatment for chronic-obstructive pulmonary disorder (COPD), a severe lung disease, but this has been paused to conduct testing on 100 patients who have been diagnosed with Covid-19.
It was identified in a WHO analysis of potential treatments against the coronavirus. Patients can self-administer it, through a small hand-held battery-operated nebulizer.
The trial is due to start next week.